Kornimate/medical-research-clean huggingface dataset:
alteration of symbiosis intestinal microbiota on patients with anorexia nervosa

Conditions: Anorexia Nervosa; Dysbiosis; Anxious Depression

Summary: the purpose of this study will be to study the association between the level of psychic symptomatic of anorexia nervosa (an) (intensity of food restriction, symptoms of anxiety and depression) and alteration of host environment symbiosis and the mechanism (dysbiosis of intestinal microbiota, increase of intestinal permeability, immunity alteration and low-grade inflammation).

this is a monocentric study aims to characterise the intestinal microbiota of anorexia nervosa patients with malnutrition, in comparison with the control subject, by dna sequencing and metagenomic method. the interaction of intetinal microbiota with the host will be studied through the mecanistic studies and various parameters of alteration of symbiosis (intestinal permeability, inflammation) and their association with psychic symptoms of anorexia nervosa. the objective of this approche is to have not only a descrition of genomic of material of sampling, but also an overview of its potential functioning.

Eligibility criteria:
inclusion criteria: for patients: * patients aged ≥18 years; * anorexia according to dsm-5 and cidi (composite international diagnostic interview); * body mass index (bmi) (p/t2) \< 15; * hospitalization for nutrition rehabilitation; * covered by a health insurance; * informed consent form signed. for healthy volunteers: * aged ≥18 years; * 18.5 \< bmi (p/t2) \< 25; * covered by a health insurance; * informed consent form signed. exclusion criteria: for patients: * patients no-responding all criteria of dsm-5 or cidi scores; * taken of antibiotic treatment 2 months / or laxativ 3 weeks before hospitalization; * somatic comorbidity should perturb intestinal microbiota (crohn's disease, diabetes and all other chronic inflammatory diseases); * patients under guardianship; * patients covered by french ame scheme. for healthy volunteers: * any disease should perturb intestinal microbiota; * recent ponderal variation; * taken of antibiotic treatment 2 months or laxativ 3 weeks before hospitalization; * under guardianship; * covered by french ame scheme.

Keywords: anorexia nervosa dysbiosis anxious depression intestinal microbiota body mass index
effect of nasaleze on nasal challenge with allergen

Conditions: Allergic Rhinitis

Summary: the objectives of this protocol are: 1. to confirm the inhibitory effect of nasaleze on the immediate response to nasal challenge with antigen, and 2. to show that inhibition of the immediate response to nasal challenge with antigen by nasaleze inhibits subsequent inflammatory events.


Eligibility criteria:
inclusion criteria 1. males and females between 18 and 45 years of age. 2. history of grass and/or ragweed allergic rhinitis. 3. positive skin test to grass and/or ragweed antigen. 4. positive response to screening nasal challenge. exclusion criteria: 1. physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease. 2. pregnant or lactating women. 3. upper respiratory infection within 14 days of study start. 4. fev1\<80% of predicted at screening for subjects with history of mild asthma.
prehabilitation for patients undergoing transcatheter aortic valve replacement

Conditions: Aortic Valve Stenosis

Summary: in this pilot study, investigators aim to identify patients undergoing tavr who are at elevated risk for adverse clinical events due to decreased exertional capacity and physical deconditioning. investigators aim to determine if monitored pre-procedural physical therapy is safe in these patients. lastly, investigators aim to assess the efficacy of prehabilitation 1. to improve physical functioning by the time of tavr and to sustain benefit through 30 days post-procedure; and 2. to determine its effect on post-procedural length-of-stay, clinical outcomes, and quality of life.


Eligibility criteria:
inclusion criteria: * subject must be ambulatory (with or without an assist device) * subject has severe aortic stenosis and is felt an appropriate candidate for tavr by the heart team. * subject requires 6.0 seconds or longer to complete a 15ft walk test * subject must be able to move between sitting and standing without assistance from another person. * subject has adequate iliac and femoral arterial anatomy to allow for tavr via transfemoral access * subject is 18 years of age or greater * subject is willing to give consent and participate in the study exclusion criteria: * subject is incapable of following instructions * subject is unable to meet the minimum required physical therapy visits * subject has other medical conditions rendering it unsafe, in the opinion of the principal investigator and physical therapy staff, to perform a 6 minute walk test or physical therapy conditioning prior to tavr * subject has significant severe un-revascularized epicardial coronary disease.

Keywords: tavr elevated frailty score transcatheter valve replacement
intravascular access of covid-19 patient under personal protective equipment

Conditions: Cardiac Arrest; Emergencies

Summary: the current covid-19 pandemic, this is especially since the transmission of sars-cov-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients covid-19 disease may be asymptomatic. as recommended by the cdc medical personnel should be equipped with full personal protective equipment (ppe) for agp in contact with suspected/confirmed covid-19 patient. therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.


Eligibility criteria:
inclusion criteria: * paramedic * consent voluntary participation in the study * none experience in resuscitation with personal protective equipment exclusion criteria: * refusal to participate in the study

Keywords: intravascular access covid-19 personal protective equipment medical simulation
treatment of post stroke fatigue with a wakefulness promoting agent

Conditions: Stroke; Post Stroke Fatigue

Summary: this study is an investigator initiated placebo controlled double blinded trial. the hypothesis is that treatment with modafinil positively will affect behavioural and cognitive rehabilitation after stroke, causing the treatment group to experience decreased fatigue, increased endurance, improved skills of sustaining attention and faster reaction times. the cognitive rehabilitation will show in increased muscle mass, decreased osteoporosis and better physical performances due to a higher level of physical activity.


Eligibility criteria:
inclusion criteria: * 18 years of age and stroke within 14 days * modified rankin scale 3 or under and barthel 85 or over before stroke * person that can understand instruction and do tests and questionnaires on their own or with support * has given informed consent * mfi-20 score of 12 or more * infertile person or fertile women tested negative of pregnancy and using safe anticonception exclusion criteria: * dementia or other neuropsychiatric disease making the person incapable of understanding instructions * other disease with fatigue as a known symptom * stroke induced by trauma, infection or surgical procedure * former drug abuse * known contraindication to treatment with modafinil * known active malignancy, benign intracranial tumor, subdural or epidural bleeding * kidneydysfunction with creatinin more than 265 micromol/l or liver disease with asat (aspartate aminotransferase) elevated to more than 70 u/l for women or 100 u/l for men. * allergy to project treatment * use of benzodiazepin or antiepileptic drugs in a fixed dose. sleeping pills not included. * patients threaded with ciclosporin or anti hiv medication

Keywords: stroke fatigue modafinil
incentive processing and learning in anorexia nervosa and bulimia nervosa

Conditions: Anorexia Nervosa; Bulimia Nervosa

Summary: the purpose of this study is to investigate areas of the brain responsible for 'liking', 'wanting', and learning in adults with eating disorders using brain imaging techniques, computer tasks, a test meal, and self-report questionnaires and interviews. the investigators will study changes in brain activity using a procedure called functional magnetic resonance imaging (fmri). this study will include 252 women with an eating disorder (63 an-restricting type (an-r), 63 an-binge eating/purging type (an-bp), 63 bulimia nervosa (bn)) and 63 healthy controls (hc) aged 18-39. aim 1: to examine neural differences in 'liking' and 'wanting' in ed relative to hc. aim 2: to examine differences in instrumental learning for reward and punishment in ed relative to hc. aim 3: to examine how 'liking' and 'wanting' drive instrumental learning in ed and predict clinical symptoms at baseline and 1 year later. exploratory aim: to explore the associations of dopamine function, as measured by neuromelanin mri (nm-mri), with ed diagnosis and brain response to 'liking', 'wanting', and learning.


Eligibility criteria:
inclusion criteria: eating disorder group: * between the ages of 18 and 39 years old * meet dsm-v criteria for an-r, an-bp, or bn healthy control group: * between the ages of 18 and 39 years old * have maintained 85% to 120% ideal body weight since menarche exclusion criteria: all groups: * psychotic illness/other mental illness requiring hospitalization * current dependence on drugs or alcohol defined by dsm iv criteria. additionally, positive test results for drug use on the day of the scan, apart of marijuana, will result in cancelling or rescheduling the scan because acute use will impact mri measures. * physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight * neurological disorder, neurodevelopmental disorder, or history of head injury with \>30 min loss of consciousness * any contraindication to undergoing an mri * primary obsessive compulsive disorder or primary major depressive disorder additional exclusion criteria for ed group: -if taking other psychotropic medication, any change in dosage in the 2 weeks before scanning additional exclusion criteria for healthy control group: * meet criteria for the diagnosis of any psychiatric disorder currently * any history of binge eating or purging behaviors, including self-induced vomiting, laxative or diuretic misuse * use of any psychoactive or other medication known to affect mood or concentration in the last 3 months
pethema lal-ri/96: treatment for patients with standard risk acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia

Summary: the objective of current protocol is try improve the results of chemotherapy treatment in patients with all wich is not indicated the peripheral stem cell transplant in first remission, with an intensive consolidation follow by re-inductions.

induction therapy: patients with standard risk receive vincristine (1,5 mg/m2)iv on days 1, 8, 15 and 22;daunorubicin (30 mg/m2)iv on days 1, 8, 15 and 22; oral or iv prednisone 60 mg/m2/day, days 1 to 27 and 30 mg/m2/day, days 28 to 35;asparaginase 10.000 ui/m2 im or iv, days 10 to 12, 17 to 19 and 24 to 26;cyclophosphamide (500 mg/m2)iv days 1, 2 and 29; methotrexate, cytosine arabinoside and hydrocortisone, days 1 to 22. patients older than 55 years are not treated with asparaginase and cyclophosphamide. consolidation therapy (1): standard risk: mercaptopurine 50 mg/m2, po, days 1 to 7, 28-35 and 56-63; methotrexate (3g/m2)iv/24 hours, day 1, 28 and 56; vm-26 (150 mg/m2)/12 hours, iv, days 14 and 42; ara-c (500 mg/m2)/12 hours, iv days 14-15 and 42-43; intrathecally treatment, days 1, 28 and 56. patients over 50 years: mercaptopurine (50 mg/m2), po, days 1 to 7, 28-35 and 56-63;methotrexate (1,5 g/m2) iv/24 hours, day 1, 28 and 56; vm-26 (150 mg/m2)/12 hours, iv days 14 and 42; ara-c (500 mg/m2)/12 hours, iv days 14-15 and 42-43; intrathecally treatment, days 1, 28 and 56. consolidation therapy (2)/reinduction: one cycle similar to induction. it starts one week after last dose of mercaptopurine.dexamethasone 10 mg/m2/day,po or iv, days 1-14 and 5 mg/m2/day, po or iv days 15-21; vcr: 1,5 mg/m2 iv, days 1, 8 and 15; daunorubicin 30 mg/m2 iv, days 1, 2, 8 and 9; cyclophosphamide 600 mg/m2/day iv, days 1 and 15; asparaginase: 10.000 ui/m2 im or iv, days 1-3 and 15-17;intrathecally treatment days 1 and 15 maintenance therapy 1:administration of continuous chemotherapy (mercaptopurine and methotrexate) and reinductions until one year from diagnosis. * continuous chemotherapy: * mp 50 mg/m2/day po * mtx 20 mg/m2/week im * reinductions * vcr: 1,5 mg/m2 iv, day 1. * pdn: 60 mg/m2/day, iv or po days 1 to 7 * l-asa: 20.000 ui/m2, im or iv day 1. * intrathecally day 1 seven cycles, weeks 25, 29, 33, 37, 41, 45 and 49. maintenance therapy 2:administration of continuous chemotherapy (mercaptopurine and methotrexate) while second year from diagnosis (weeks 53 to 104). * mp 50 mg/m2/day, po * mtx 20 mg/m2/week, im.

Eligibility criteria:
inclusion criteria: * adults (over 15 years) with all standard risk no prior antiblastic chemotherapy exclusion criteria: * mature b-all (fabl3) or with cytogenetic all "burkitt-like" alterations (t\[8;14\], t\[2;8\], t\[8;22\]) * mixed forms of all * acute leukemia no differentiate * patients with coronary disorders, valvular or hypertensive cardiopathy * patients with chronic liver disorders * chronic pulmonary disorders * renal insufficiency * neurologic disfunctions * ecog 3 and 4 * no signed consent form
study of sildenafil effects in combination with rehabilitation in patients with chronic obstructive pulmonary disease (copd) and associated pulmonary hypertension

Conditions: COPD; Pulmonary Hypertension

Summary: sildenafil is a phosphodiesterase-5 inhibitor that has been approved for the treatment of pulmonary arterial hypertension with orphan drug designation. sildenafil modulates the nitric oxide (no) pathway in the vessel wall. since this pathway is impaired in pulmonary arteries of patients with pulmonary hypertension (ph) associated with chronic obstructive pulmonary disease (copd), the investigators hypothesized that sildenafil might improve pulmonary hemodynamics and increase exercise tolerance in this condition.

it is a prospective, randomized, double-blind, placebo controlled trial to assess the effect of 3 months treatment with sildenafil (20 mg/8 h), added to a pulmonary rehabilitation program, on exercise tolerance. subjects: 60 patients (30 by treatment group). main end-point variable: endurance time in constant work exercise test (cwet). other measurements: 6 min walk distance, performance in incremental exercise test, physiological and metabolic response at iso-time and iso-load in cwet, dyspnea, and health-related quality of life.

Eligibility criteria:
inclusion criteria: * copd, fev1 \< 80% ref. and fev1/fvc \< 0.7 post bronchodilator * age 40-80 years * pulmonary hypertension * consent to participate in the study exclusion criteria: * pulmonary or extrapulmonary disease that modifies gas exchange or pulmonary hemodynamics * recent exacerbation (\<4 weeks) (temporally) * patients treated with nitrates or cyp3a4 inhibitors (ketoconazole, itraconazole, ritonavir) * ischemic optic neuropathy * patients treated with phosphodiesterase-5 inhibitors * patients with ischemic cardiopathy * systemic disease that could modified the results * patients unable to practise exercise

Keywords: exercise tolerance copd pulmonary hypertension sildenafil
three different oral hygiene regimes on three volatile sulfur compounds

Conditions: Halitosis

Summary: the purpose of the study is to evaluate the effect of various oral hygiene regimes on three volatile sulfur compounds.

thirty male monk volunteers who matched with the including criteria were divided randomly into two groups. both groups were practiced to brush their teeth with scrubbing method for one week. then, each group were instructed to do different additional protocol regimen- group a have to do mouth washing and tooth brushing and group b have to practice tongue cleaning addition to tooth brushing for three weeks. at the fifth week, both groups were instructed to practice tooth brushing, mouth washing and tongue cleaning. three different volatile sulfur compounds were measured by oral chroma. tongue characteristics, oral examination were checked as the outcomes of this study.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of oral malodor * no systemic diseases and no severe dental diseases * at least 20 functional teeth exclusion criteria: * risky oral habit (smoking and betel quid chewing) * current use of antibiotics or any drugs * current use of any kind of mouthwash
safety and effectiveness of the hydrus microstent

Conditions: Open Angle Glaucoma; Primary Open Angle Glaucoma; Pseudoexfoliation Glaucoma; Pigmentary Glaucoma

Summary: the purpose of this study is to assess the safety and effectiveness of the hydrus microstent for lowering intraocular pressure (iop) in pseudophakic patients with open-angle glaucoma for whom iop is not sufficiently controlled on topical hypotensive medication and prior to incisional glaucoma surgery.

qualified subjects will undergo ocular hypotensive medication washout prior to implantation with the hydrus microstent. following implantation on day 0, subjects will attend 8 scheduled postoperative visits: day 1, week 1, month 1, month 3, month 6, month 12, month 18, and month 24. a decision to terminate the study was made by the sponsor arising from challenges with enrollment of the target study population, leading to suspension of enrollment and revision of the follow-up period to 12 months. the total duration of participation for each subject was approximately 13 months including the medication washout prior to implantation. this study was initiated by ivantis, inc. ivantis was acquired by alcon research, and alcon assumed sponsorship of the study in november 2022.

Eligibility criteria:
inclusion criteria: * early or moderate glaucomatous optic nerve damage; * uncomplicated cataract surgery with well centered posterior chamber iol greater than or equal to 365 days prior to the screening visit; * inadequately controlled iop; * shaffer angle grade iii-iv in all four quadrants; * age appropriate minimum central endothelial cell density; * other protocol-defined inclusion criteria may apply. exclusion criteria: * diagnosis of acute angle closure, chronic angle closure, or congenital, malignant, or developmental glaucoma; * requires oral hypotensive medications; * shallow or flat anterior chamber; * prior glaucoma surgery; * ocular hypertension; * other protocol-defined exclusion criteria may apply.
phase iii study comparing 3d conformal radiotherapy and conformal radiotherapy imrt to treat endometrial cancer

Conditions: Endometrial Cancer

Summary: comparison of radiotherapy tolerance (two types of radiotherapy) for patients over 70 years with a endometrial cancer.

endometrial cancer is the most common form of gynecological cancer in france with 6560 new cases in 2010. endometrial cancers occurs generally after menopause but are sometimes diagnosticated before 40 years. the 5 years overall survival of endometrial cancer is 76% (95% for non locally advanced or non metastatic disease). some factors are involved in disease prognostic: age, geographical origin, physical status, tumor grade, tumor histology and probably biomarkers. some studies demonstrated that advanced age is a negative prognostic factor due to higher relapse risk and higher specific mortality. unfortunately, incidence of endometrial cancer will probably increase in future due to aging of the occidental population. current treatment of endometrial cancer is based on post-operative radiation therapy: adjuvant brachytherapy or adjuvant external beam radiation therapy. however these techniques lead to serious toxicity (digestive toxicity, ileitis...) in elder patient. consequently, pelvic radiation therapy is difficult to organize before 75 years and dangerous to perform after 80 years. however a new technique called: intensity-modulated radiation therapy (imrt) can make the difference. imrt is a new high precision radiotherapy technique probably well adapted for old people, with less toxicity than current radiotherapy. nevertheless, imrt is not recognized as a standard radiation therapy procedure in france and europe. thus, goal of tomogyn study is to compare the tolerance of old women (at least 70 years), with endometrial cancer, treated with external beam radiation therapy or imrt.

Eligibility criteria:
inclusion criteria: * endometrial adenocarcinoma histologically proven * post op pelvic radiotherapy * age ≥ 70 * performance status ≤ 2 * mmse ≥ 10 * life expectancy ≥ 3 months * social security covered * signed informed consent exclusion criteria: * type i stade iagi and stade iagiii without myometer infiltration, stade iiic2 and iv adenocarcinoma * uterine sarcoma * surgery not in accordance with recommendations of inca * previous uncontrolled or less than 5 years prior to diagnosis cancer * cons-indication for radiotherapy * diarrhea ≥ 3 per day * pelvic lymph nodes \> 1cm not resected during staging * previous sigmoid diverticulitis, crohn disease, systemic disease, ulcerative haemorrhagic, collagenosis, infectious peritonitis * imrt other than tomotherapy * photon energy \< 10mv * patient under guardianship

Keywords: endometrial cancer imrt age over 70
outcome of fetal spina bifida

Conditions: Pregnancy; Fetal and Neonatal Health

Summary: neural tube defects are one of the most prevalent congenital abnormalities, surpassed only by cardiac malformations. spina bifida accounts for the majority of the neural tube defects and is comprised of a wide spectrum of anomalies ranging from small isolated sacral dysraphisms to large spinal defects. the origin of spina bifida is a failure of neurulation. it usually occurs at 15 days post-conception, resulting in a bony spinal defect with extrusion of the neural placode and/or the meninges outside of the spinal canal. spina bifida has a prevalence of 1-5 in 1,000 live births and is the most complex congenital abnormality compatible to long-time survival. concerning psychomotor development as well as urinary bladder and intestinal morbidity the prognosis ranges from normal functional outcome to severe disability. the diagnosis of serious fetal abnormalities such as spinal dysraphism by ultrasound screening allows patients to prepare for the birth of an impaired child or to consider termination of the pregnancy. in current practice, prenatal counseling and obstetric management depend not only on the detection of a spinal dysraphism but also on an appropriate assessment of the severity of the defect and its possible impact on the postnatal development of the affected child. level and type of lesion, presence of associated anomalies (e.g., chiari ii malformation and ventriculomegaly) and mode of surgical closure are factors known to have prognostic impact on the postnatal outcome. previous studies reported that postnatally determined lesion levels correlated well with functional status and survival. on the contrary, it is still not clear whether similar data obtained antenatally are of value. in this study, the investigators will review their database of all cases of prenatally diagnosed spina bifida within a 16 year period between 1993 and 2009. by analyzing the prenatal and postnatal characteristics of fetuses with spina bifida in relation to the anatomic level of the lesion, the investigators aim to contribute further information regarding the natural course of affected pregnancies and the correlation of prenatal ultrasound findings with their functional outcome.


Eligibility criteria:
inclusion criteria: * spina bifida identified at prenatal ultrasound examination * ultrasound diagnosis between 1993 - 2009 exclusion criteria: * deviant postnatal diagnosis * loss to follow-up * incomplete data

Keywords: prenatal diagnosis ultrasound outcome spina bifida neural tube defect